• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Sensei Biotherapeutics Inc. (Amendment)

    3/7/24 6:00:48 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNSE alert in real time by email
    SC 13D/A 1 formsc13da.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

    (Rule 13d-101)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

     

    (Amendment No. 2)1

     

    Sensei Biotherapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    81728A108

    (CUSIP Number)

     

    NEWTYN MANAGEMENT, LLC

    60 East 42nd, 9th Floor

    New York, New York 10165

    (212) 446-2465

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    March 5, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

    1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 81728A108

     

    1 NAME OF REPORTING PERSON  
         
      Newtyn Partners, LP  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
        (b) ☐
         
    3 SEC USE ONLY  
         
         
    4 SOURCE OF FUNDS  
         
      WC  
    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ☐
         
         
    6 CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

    7 SOLE VOTING POWER
       
    NUMBER OF   -0-
    SHARES 8 SHARED VOTING POWER
    BENEFICIALLY    
    OWNED BY   554,493
    EACH 9 SOLE DISPOSITIVE POWER
    REPORTING    
    PERSON WITH   -0-
      10 SHARED DISPOSITIVE POWER
         
        554,493

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      554,493     
    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐
         
         
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      2.21%  
    14 TYPE OF REPORTING PERSON  
         
      PN  

     

    2
     

     

    CUSIP No. 81728A108

     

    1 NAME OF REPORTING PERSON  
         
      Newtyn TE Partners, LP  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
        (b) ☐
         
    3 SEC USE ONLY  
         
         
    4 SOURCE OF FUNDS  
         
      WC  
    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ☐
         
         
    6 CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

    7 SOLE VOTING POWER
       
    NUMBER OF   -0-
    SHARES 8 SHARED VOTING POWER
    BENEFICIALLY    
    OWNED BY   687,752
    EACH 9 SOLE DISPOSITIVE POWER
    REPORTING    
    PERSON WITH   -0-
      10 SHARED DISPOSITIVE POWER
         
        687,752

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      687,752     
    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐
         
         
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      2.74%  
    14 TYPE OF REPORTING PERSON  
         
      PN  

     

    3
     

     

    CUSIP No. 81728A108

     

    1 NAME OF REPORTING PERSON  
         
      Newtyn Management, LLC  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
        (b) ☐
         
    3 SEC USE ONLY  
         
         
    4 SOURCE OF FUNDS  
         
      OO  
    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ☐
         
         
    6 CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      New York  

    7 SOLE VOTING POWER
       
    NUMBER OF   -0-
    SHARES 8 SHARED VOTING POWER
    BENEFICIALLY    
    OWNED BY   1,242,245
    EACH 9 SOLE DISPOSITIVE POWER
    REPORTING    
    PERSON WITH   -0-
      10 SHARED DISPOSITIVE POWER
         
        1,242,245

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      1,242,245     
    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐
         
         
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      4.95%  
    14 TYPE OF REPORTING PERSON  
         
      OO  

     

    4
     

     

    CUSIP No. 81728A108

     

    1 NAME OF REPORTING PERSON  
         
      Newtyn Capital Partners, LP  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
        (b) ☐
         
    3 SEC USE ONLY  
         
         
    4 SOURCE OF FUNDS  
         
      OO  
    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ☐
         
         
    6 CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

    7 SOLE VOTING POWER
       
    NUMBER OF   -0-
    SHARES 8 SHARED VOTING POWER
    BENEFICIALLY    
    OWNED BY   1,242,245
    EACH 9 SOLE DISPOSITIVE POWER
    REPORTING    
    PERSON WITH   -0-
      10 SHARED DISPOSITIVE POWER
         
        1,242,245

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      1,242,245     
    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐
         
         
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      4.95%  
    14 TYPE OF REPORTING PERSON  
         
      PN  

     

    5
     

     

    CUSIP No. 81728A108

     

    1 NAME OF REPORTING PERSON  
         
      Ledo Capital, LLC  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
        (b) ☐
         
    3 SEC USE ONLY  
         
         
    4 SOURCE OF FUNDS  
         
      OO  
    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ☐
         
         
    6 CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      New York  

    7 SOLE VOTING POWER
       
    NUMBER OF   -0-
    SHARES 8 SHARED VOTING POWER
    BENEFICIALLY    
    OWNED BY   1,242,245
    EACH 9 SOLE DISPOSITIVE POWER
    REPORTING    
    PERSON WITH   -0-
      10 SHARED DISPOSITIVE POWER
         
        1,242,245

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      1,242,245     
    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐
         
         
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      4.95%  
    14 TYPE OF REPORTING PERSON  
         
      OO  

     

    6
     

     

    CUSIP No. 81728A108

     

    1 NAME OF REPORTING PERSON  
         
      Noah Levy  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
        (b) ☐
         
    3 SEC USE ONLY  
         
         
    4 SOURCE OF FUNDS  
         
      OO  
    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ☐
         
         
    6 CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      USA  

    7 SOLE VOTING POWER
       
    NUMBER OF   -0-
    SHARES 8 SHARED VOTING POWER
    BENEFICIALLY    
    OWNED BY   1,242,245
    EACH 9 SOLE DISPOSITIVE POWER
    REPORTING    
    PERSON WITH   -0-
      10 SHARED DISPOSITIVE POWER
         
        1,242,245

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      1,242,245     
    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐
         
         
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      4.95%  
    14 TYPE OF REPORTING PERSON  
         
      IN  

     

    7
     

     

    CUSIP No. 81728A108

     

    The following constitutes the Schedule 13D filed by the undersigned (the “Schedule 13D”).

     

    Item 1. Security and Issuer.

     

    This statement relates to the Common Stock, $0.0001 par value per share (the “Shares”), of Sensei Biotherapeutics, Inc., a Delaware corporation (the “Issuer”). The address of the principal executive offices of the Issuer is 1405 Research Blvd, Suite 125, Rockville, Maryland 20850.

     

    Item 2. Identity and Background.

     

    (a) This statement is filed by:

     

    (i)   Newtyn Partners, LP, a Delaware limited partnership (“NP”), with respect to the Shares directly and beneficially owned by it;
         
    (ii)   Newtyn TE Partners, LP, a Delaware limited partnership (“NTE”), with respect to the Shares directly and beneficially owned by it;
         
    (iii)   Newtyn Management, LLC, a New York limited liability company (“NM”), as the investment manager of each of NP and NTE;
         
    (iv)   Newtyn Capital Partners, LP, a Delaware limited partnership (“NCP”), as the general partner of each of NP and NTE;
         
    (v)   Ledo Capital, LLC, a New York limited liability company (“Ledo”), as the general partner of NCP; and
         
    (vi)  

    Noah Levy, as the managing member of each of NM and Ledo.

     

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.” Each of the Reporting Persons is party to that certain Joint Filing Agreement, as further described in Item 6. Accordingly, the Reporting Persons are hereby filing a joint Schedule 13D.

     

    (b) The principal business address of each of the Reporting Persons is 60 East 42nd Street, 9th Floor, New York, New York 10165.

     

    (c) The principal business of each of NP and NTE is investing in securities. The principal business of NM is serving as the investment manager of each of NP and NTE. The principal business of NCP is serving as the general partner of each of NP and NTE. The principal business of Ledo is serving as the general partner of NCP. The principal occupation of Mr. Levy is serving as the managing member of each of NM and Ledo.

     

    (d) No Reporting Person has, during the last five (5) years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e) No Reporting Person has, during the last five (5) years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f) Mr. Levy is a citizen of the United States of America.

     

    8
     

     

    CUSIP No. 81728A108

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    The Shares purchased by each of NP and NTE were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). The aggregate purchase price of the 554,493 Shares beneficially owned by NP is approximately $807,535, including brokerage commissions. The aggregate purchase price of the 687,752 Shares beneficially owned by NTE is approximately $1,031,194, including brokerage commissions.

     

    Item 4. Purpose of Transaction.

     

    The Reporting Persons purchased the Shares based on their belief that the Shares, when purchased, constituted an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable.

     

    On October 25, 2023, the Reporting Persons delivered a letter (the “Offer Letter”) to the Board of Directors (the “Board”) of the Issuer conveying a proposal to acquire 100% of the Issuer’s outstanding Shares at a price equal to $1.00 per share in cash, representing a premium of approximately 67% over the closing price as of the close of business on October 25, 2023 (the “Proposal”). The Reporting Persons submitted the Proposal to the Board in order to facilitate constructive discussions, with the goal of entering into a mutually agreeable transaction that is in the best interests of all stockholders. A copy of the Offer Letter is attached hereto as Exhibit 99.1 and is incorporated herein by reference. On November 6, 2023, the Board rejected the Proposal.

     

    The Reporting Persons do not have any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. Depending on various factors including, without limitation, the Issuer’s financial position, results and strategic direction, actions taken by the Issuer’s management and the Board, other investment opportunities available to the Reporting Persons, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, engaging in communications and information exchanges with the Issuer’s management and Board, engaging in discussions with shareholders of the Issuer or other third parties about the Issuer and the Reporting Persons’ investment, making recommendations concerning changes to the Issuer’s operations, governance or capitalization, potential business combinations or dispositions involving the Issuer or certain of its businesses, or suggestions for improving the Issuer’s financial and/or operational performance, acquiring additional Shares, disposing of some or all of Shares, or changing their intention with respect to any and all matters referred to in Item 4.

     

    Item 5. Interest in Securities of the Issuer.

     

    The aggregate percentage of Shares reported owned by each person named herein is based upon 25,070,980 Shares outstanding as of February 23, 2024, which is the total number of Shares outstanding as reported in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 29, 2024.

     

    9
     

     

    CUSIP No. 81728A108

     

    A. NP

     

    (a)

    As of the date hereof, NP directly owned 554,493 Shares.

     

    Percentage: Approximately 2.21%

     

    (b)

    1. Sole power to vote or direct vote: 0

    2. Shared power to vote or direct vote: 554,493

    3. Sole power to dispose or direct the disposition: 0

    4. Shared power to dispose or direct the disposition: 554,493

     

    B. NTE

     

    (a) As of the date hereof, NTE directly owned 687,752 Shares.

     

    Percentage: Approximately 2.74%

     

    (b)

    1. Sole power to vote or direct vote: 0

    2. Shared power to vote or direct vote: 687,752

    3. Sole power to dispose or direct the disposition: 0

    4. Shared power to dispose or direct the disposition: 687,752

     

    C. NM

     

    (a) NM, as the investment manager of each of NP and NTE, may be deemed to beneficially own the 1,242,245 Shares owned in the aggregate by NP and NTE.

     

    Percentage: Approximately 4.95%

     

    (b)

    1. Sole power to vote or direct vote: 0

    2. Shared power to vote or direct vote: 1,242,245

    3. Sole power to dispose or direct the disposition: 0

    4. Shared power to dispose or direct the disposition: 1,242,245

     

    D. NCP

     

    (a) NCP, as the general partner of each of NP and NTE, may be deemed to beneficially own the 1,242,245 Shares owned in the aggregate by NP and NTE.

     

    Percentage: Approximately 4.95%

     

    (b) 1. Sole power to vote or direct vote: 0
    2. Shared power to vote or direct vote: 1,242,245
    3. Sole power to dispose or direct the disposition: 0
    4. Shared power to dispose or direct the disposition: 1,242,245

     

    E. Ledo

     

    (a) Ledo, as the general partner to NCP, may be deemed to beneficially own the 1,242,245 Shares owned in the aggregate by NP and NTE.

     

    10
     

     

     CUSIP No. 81728A108

     

    Percentage: Approximately 4.95%

     

    (b)

    1. Sole power to vote or direct vote: 0

    2. Shared power to vote or direct vote: 1,242,245

    3. Sole power to dispose or direct the disposition: 0

    4. Shared power to dispose or direct the disposition: 1,242,245

     

    F. Mr. Levy

     

    (a) Mr. Levy, as managing member of each of NM and Ledo, may be deemed to beneficially own the 1,242,245 Shares owned in the aggregate by NP and NTE.

     

    Percentage: Approximately 4.95%

     

    (b)

    1. Sole power to vote or direct vote: 0

    2. Shared power to vote or direct vote: 1,242,245

    3. Sole power to dispose or direct the disposition: 0

    4. Shared power to dispose or direct the disposition: 1,242,245

     

    The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer that he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.

     

    (c) The transactions in the Shares during the past 60 days by certain of the Reporting Persons are set forth on Schedule A attached hereto and are incorporated herein by reference.

     

    (d) No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares.

     

    (e) As of March 5, 2024, each of the Reporting Persons ceased to be the beneficial owner of more than 5% of the Issuer’s outstanding Common Stock.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

     

    On November 3, 2023, the Reporting Persons entered into a Joint Filing Agreement in which the Reporting Persons agreed to the joint filing on behalf of each of them of statements on Schedule 13D with respect to the securities of the Issuer. The Joint Filing Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    Other than as described herein, there are no contracts, arrangements, understandings or relationships among the Reporting Persons, or between the Reporting Persons and any other person, with respect to the securities of the Issuer.

     

    Item 7. Material to be Filed as Exhibits.

     

    99.1

    Offer Letter, dated October 25, 2023 (incorporated by reference to Exhibit 99.1 to Schedule 13D filed by Newtyn Partners, LP, Newtyn TE Partners, LP, Newtyn Management, LLC, Newtyn Capital Partners, LP, Ledo Capital, LLC and Noah Levy on November 3, 2023).

       
    99.2 Joint Filing Agreement, dated November 3, 2023 (incorporated by reference to Exhibit 99.2 to Schedule 13D filed by Newtyn Partners, LP, Newtyn TE Partners, LP, Newtyn Management, LLC, Newtyn Capital Partners, LP, Ledo Capital, LLC and Noah Levy on November 3, 2023).

     

    11
     

     

    CUSIP No. 81728A108

    SIGNATURES

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: March 7, 2024

     

      Newtyn Partners, LP
         
      By: Newtyn Management, LLC Investment Manager
         
      By: /s/ Eugene Dozortsev
      Name: Eugene Dozortsev
      Title: Authorized Signatory
         
      Newtyn TE Partners, LP
         
      By: Newtyn Management, LLC Investment Manager
         
      By: /s/ Eugene Dozortsev
      Name: Eugene Dozortsev
      Title: Authorized Signatory
         
      Newtyn Management, LLC
         
      By: /s/ Eugene Dozortsev
      Name: Eugene Dozortsev
      Title: Authorized Signatory
         
      Newtyn Capital Partners, LP
         
      By: Ledo Capital, LLC General Partner
       
      By: /s/ Eugene Dozortsev
      Name: Eugene Dozortsev
      Title: Authorized Signatory

     

      Ledo Capital, LLC
       
      By: /s/ Eugene Dozortsev
      Name: Eugene Dozortsev
      Title: Authorized Signatory

     

    12
     

     

    CUSIP No. 81728A108

     

      /s/ Noah Levy
      Noah Levy

     

    13
     

     

    CUSIP No. 81728A108

    SCHEDULE A

     

    The following table details the transactions by the Reporting Persons in Shares of Common Stock during the period commencing sixty (60) days prior to March 6, 2024.

     

    Nature of the

    Transaction

      Securities
    Purchased/(Sold)
       Price Per
    Share($)
       Date of
    Purchase / Sale
    NEWTYN PARTNERS, LP
    Sale of Common Stock   (574)   0.8170   2/2/2024
    Sale of Common Stock   (2,728)   0.8149   2/5/2024
    Sale of Common Stock   (18,136)   0.8342   2/6/2024
    Sale of Common Stock   (31,389)   0.8244   2/9/2024
    Sale of Common Stock   (500)   0.8425   2/12/2024
    Sale of Common Stock   (9,193)   0.7942   2/13/2024
    Sale of Common Stock   (10,010)   0.7725   2/16/2024
    Sale of Common Stock   (13,250)   0.7735   2/21/2024
    Sale of Common Stock   (1,338)   0.7641   2/23/2024
    Sale of Common Stock   (10,000)   0.7850   2/26/2024
    Sale of Common Stock   (22,892)   0.7824   2/27/2024
    Sale of Common Stock   (31,373)   0.8398   2/28/2024
    Sale of Common Stock   (31,508)   0.8496   2/29/2024
    Sale of Common Stock   (9,000)   0.8356   3/1/2024
    Sale of Common Stock   (53,441)   0.8746   3/4/2024
    Sale of Common Stock   (22,423)   0.8952   3/5/2024

     

    The following table details the transactions by the Reporting Persons in Shares of Common Stock during the period commencing March 6, 2024 through the filing date.

     

    Nature of the

    Transaction

      Securities
    Purchased/(Sold)
       Price Per
    Share($)
       Date of
    Purchase / Sale
    NEWTYN PARTNERS, LP
    Sale of Common Stock   (9,979)   0.9336   3/6/2024
    Sale of Common Stock   (13,041)   0.9437   3/7/2024

     

     

     

    Get the next $SNSE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNSE

    DatePrice TargetRatingAnalyst
    5/14/2024$5.00Overweight
    Stephens
    3/10/2022$12.00 → $10.00Overweight
    Piper Sandler
    7/1/2021$12.00Buy → Hold
    Berenberg
    6/29/2021$30.00 → $14.00Outperform → Perform
    Oppenheimer
    6/29/2021Outperform → Perform
    Oppenheimer
    More analyst ratings

    $SNSE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

      - Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter 2025, and provided corporate updates. "This was a breakthrough quarter for Sensei," said John Celebi, President and CEO. "We observed favorable signs of clinical activity in patients with PD-(L)1-resistant cancers from our dose expansi

      5/6/25 7:30:00 AM ET
      $SNSE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

      BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in the New Radiotherapy and Targeted Therapy Approaches panel at the Canaccord Genuity Horizons in Oncology Virtual Conference on Monday, April 7 at 2:00 p.m. ET. About Sensei Biotherapeutics Sensei Biotherapeutics (NASDAQ:SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tum

      4/2/25 7:30:00 AM ET
      $SNSE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

      - Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant "hot" tumor patient population - - Solnerstotug continues to demonstrate a well-tolerated safety and tolerability profile - - Achieved target enrollment in dose expansion cohort; full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the full year 2024, and

      3/28/25 7:30:00 AM ET
      $SNSE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNSE
    Leadership Updates

    Live Leadership Updates

    See more
    • Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

      - SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - - Cash runway extended into the second quarter of 2026 - BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided corporate updates. "The third quarter of 2024 saw significant progress in advancing patient enro

      11/14/24 7:30:00 AM ET
      $SNSE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

      - Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - - Strong balance sheet with cash runway into the fourth quarter of 2025 - BOSTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter ended June 30, 2024, and provided corporate updates. "Collectively, the clinical data presented on SNS-101 over the past six month

      8/6/24 7:30:00 AM ET
      $SNSE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

      - Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 ASCO Annual Meeting - - Enrollment in the dose expansion portion of the clinical study advancing - - Strong balance sheet with cash runway into fourth quarter of 2025 - BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2024, and provide

      5/9/24 7:30:00 AM ET
      $SNSE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNSE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stephens initiated coverage on Sensei Biotherapeutics with a new price target

      Stephens initiated coverage of Sensei Biotherapeutics with a rating of Overweight and set a new price target of $5.00

      5/14/24 8:02:37 AM ET
      $SNSE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler reiterated coverage on Sensei Biotherapeutics with a new price target

      Piper Sandler reiterated coverage of Sensei Biotherapeutics with a rating of Overweight and set a new price target of $10.00 from $12.00 previously

      3/10/22 10:13:48 AM ET
      $SNSE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sensei Biotherapeutics downgraded by Berenberg with a new price target

      Berenberg downgraded Sensei Biotherapeutics from Buy to Hold and set a new price target of $12.00

      7/1/21 7:32:36 AM ET
      $SNSE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNSE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT AND CEO Celebi John covered exercise/tax liability with 5,558 shares, decreasing direct ownership by 5% to 105,862 units (SEC Form 4)

      4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)

      2/26/25 6:45:30 PM ET
      $SNSE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF SCIENTIFIC OFFICER Van Der Horst Edward covered exercise/tax liability with 2,276 shares, decreasing direct ownership by 4% to 59,794 units (SEC Form 4)

      4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)

      2/26/25 6:44:32 PM ET
      $SNSE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Business Officer Krebs Stephanie

      4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)

      2/14/25 6:06:10 PM ET
      $SNSE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNSE
    SEC Filings

    See more
    • SEC Form 10-Q filed by Sensei Biotherapeutics Inc.

      10-Q - Sensei Biotherapeutics, Inc. (0001829802) (Filer)

      5/6/25 4:30:27 PM ET
      $SNSE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sensei Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)

      5/6/25 7:35:17 AM ET
      $SNSE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Sensei Biotherapeutics Inc.

      DEFA14A - Sensei Biotherapeutics, Inc. (0001829802) (Filer)

      4/11/25 8:01:43 AM ET
      $SNSE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNSE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Sensei Biotherapeutics Inc. (Amendment)

      SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)

      3/7/24 6:00:48 PM ET
      $SNSE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Sensei Biotherapeutics Inc. (Amendment)

      SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)

      2/13/24 5:34:37 PM ET
      $SNSE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Sensei Biotherapeutics Inc.

      SC 13D - Sensei Biotherapeutics, Inc. (0001829802) (Subject)

      11/3/23 5:03:47 PM ET
      $SNSE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNSE
    Financials

    Live finance-specific insights

    See more
    • Sensei Biotherapeutics Adopts Stockholder Rights Agreement

      BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced that a special committee of the Board of Directors adopted a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests and maximize value for all stockholders. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of Sensei through open market accumulation without paying all stockholders an appropriate control premium or providing the Board sufficient opportunity to make i

      3/7/23 5:15:00 PM ET
      $SNSE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights

      - SNS-101 identified as a tumor-selective anti-VISTA antibody product candidate from TMAb platform - - SNS-101 preclinical data accepted for presentation at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting; abstract available online in the Journal for ImmunoTherapy of Cancer - VISTA science symposium to be webcast Tuesday, November 16 at 4:00 p.m. ET – - Ended third quarter 2021 with cash, cash equivalents and marketable securities of 156.7 million; company reiterated cash runway at least into first half 2024 BOSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immunotherapy company focused on the discovery and development of next

      11/9/21 8:54:48 AM ET
      $SNSE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program

      - Company announced first set of pH-sensitive anti-VISTA antibodies showing significant in vivo anti-tumor activity in combination with PD-1 blockade in a human VISTA knock-in mouse model – - Company plans to select a lead SNS-VISTA candidate and initiate IND-enabling studies by year-end 2021 - SNS-401-NG on track to start IND-enabling studies in second half of 2022 – -Strong cash position of $162.5 million to support platform innovation and next generation program development - BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today reporte

      8/4/21 7:45:00 AM ET
      $SNSE
      Biotechnology: Pharmaceutical Preparations
      Health Care